We confirmed dose-dependent desialylation of HER2-expressing EMT6 mammary carcinoma cells (EMT6-HER2) by E-301 but not by trastuzumab or E-301 LOF (Fig. 2B and fig. Here, ERBB2 is linked to breast carcinoma.